Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors

References

• Reynolds A, Koenig AS, Bananis E, Singh A. When is switching warranted among biologic therapies in rheumatoid arthritis? Expert Rev Pharmacoecon Outcomes Res 2012;12:319-33
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Lionetti P, Blandizzi C, et al. Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 2014;27(1Suppl):11-32
   Web of Science ®Google Scholar
• Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-60
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mittal M, Reilly P, et al. Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol 2016;35:1769-76
   PubMed Web of Science ®Google Scholar
• Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010;69:222-5
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014;109:1771-80
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther 2013;38:1236-47
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Wendling D, Joshi A, Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 2014;30:2515-21
   PubMed Web of Science ®Google Scholar
• Olivieri I, Cortesi PA, de Portu S, et al. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clin Exp Rheumatol 2016;34:68-75
   PubMed Web of Science ®Google Scholar
• Staples MP, March L, Lassere M, et al. Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database. Rheumatology (Oxford) 2011;50:166-75
   PubMed Web of Science ®Google Scholar
• Brandt J, Braun J. Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opin Biol Ther 2006;6:99-107
   PubMed Web of Science ®Google Scholar
• Lapadula G, Marchesoni A, Armuzzi A, et al. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol 2014;27(1Suppl):33-48
   Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Impact of TNF-alpha antagonists on the quality of life in selected skin diseases. G Ital Dermatol Venereol 2013;148:243-8
   PubMed Web of Science ®Google Scholar
• Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:927-32
   PubMed Web of Science ®Google Scholar
• Hutchinson D, Tier J, Soper S, et al. The conversion of infliximab to adalimumab in stable RA patients [abstract]. Rheumatology 2005;44(Suppl1):i72
   Web of Science ®Google Scholar
• Liu Y, Skup M, Chao J. Impact of non-medical switching on healthcare costs: a claims database analysis. Abstract presentation at 20th Annual meeting of ISPOR, Philadelphia, PA, May 2015. Available at: http://www.ispor.org/ScientificPresentationsDatabase/Presentation/53795 [Last accessed 1 June 2017]
   Google Scholar
• Van Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012;61:229-34
   PubMed Web of Science ®Google Scholar
• Boktor M, Motlis A, Aravantagi A, et al. Substitution with Alternative Anti-TNFalpha Therapy (SAVANT) – outcomes of a Crohn’s disease cohort undergoing substitution therapy with certolizumab. Inflamm Bowel Dis 2016;22:1353-61
   PubMed Web of Science ®Google Scholar
• Wolf D, Skup M, Yang H, et al. Clinical outcomes associated with switching or discontinuation from anti-TNF inhibitors for nonmedical reasons. Clin Ther 2017;39:849-62.e846
   PubMed Web of Science ®Google Scholar
• Cote BR, Petersen EA. Impact of therapeutic switching in long-term care. Am J Manag Care 2008;14(11Suppl):SP23-8
   Web of Science ®Google Scholar
• Bates M. Models of natural language understanding. Proc Natl Acad Sci USA 1995;92:9977-82
   PubMed Web of Science ®Google Scholar
• Hansen BB, Bowers J. Covariate balance in simple, stratified and clustered comparative studies. Statist Sci 2008;23:219-36
   Web of Science ®Google Scholar
• Chamberlain G. Analysis of covariance with qualitative data. Rev Econ Stud 1980;48:225-38
   Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Frederiksen MT, Bendtzen K, et al. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol 2016;50:483-9
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21
   PubMed Web of Science ®Google Scholar
• Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors. Arthritis Res Ther 2011;13:R25
   PubMed Web of Science ®Google Scholar
• Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46:1191-9
   PubMed Web of Science ®Google Scholar
• Nikas SN, Voulgari PV, Alamanos Y, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006;65:257-60
   PubMed Web of Science ®Google Scholar